2025 first_quarter Filing

Monitored issues related to medical supply chain and pharmacy benefit management. Monitored issues related to drug pricing.

Issues related to plasma therapies.
H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Monitored issues related to pharmacy benefit management.

H.R. 1990, the American Innovation and R&D Competitiveness Act, as it relates to the R&D tax credit. Monitored H.R. 591, Defending American Jobs & Investment Act and H.R. 2423, Unfair Tax Prevention Act, as they relate to taxation of foreign-based multinationals. Issues related to the 2025 extension of the Tax Cut and Jobs Act provisions impacting corporations and the Orphan Drug Tax Credit.

Issues related to tariffs.